Related references
Note: Only part of the references are listed.The Clinical Significance of Iron Overload and Iron Metabolism in Myelodysplastic Syndrome and Acute Myeloid Leukemia
Sarah Weber et al.
FRONTIERS IN IMMUNOLOGY (2021)
Prospective cardiac magnetic resonance imaging survey in myelodysplastic syndrome patients: insights from an Italian network
Alessia Pepe et al.
ANNALS OF HEMATOLOGY (2021)
Acquired severe aplastic anaemia: how medical therapy evolved in the 20th and 21st centuries
Phillip Scheinberg
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Comparative Study on Iron Content Detection by Energy Spectral CT and MRI in MDS Patients
Yao Zhang et al.
FRONTIERS IN ONCOLOGY (2021)
Current challenges and unmet medical needs in myelodysplastic syndromes
Uwe Platzbecker et al.
LEUKEMIA (2021)
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS (vol 136, pg 157, 2020)
L. Malcovati et al.
BLOOD (2021)
Iron chelation therapy for myelodysplastic syndrome: a systematic review and meta-analysis
Hailing Liu et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2020)
Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts
Haifa Kathrin Al-Ali et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes A Randomized Trial
Emanuele Angelucci et al.
ANNALS OF INTERNAL MEDICINE (2020)
Do Recent Randomized Trial Results Influence which Patients with Myelodysplastic Syndromes Receive Iron Chelation?
Norbert Gattermann
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2020)
Controversies on the Consequences of Iron Overload and Chelation in MDS
Francesca Vinchi et al.
HEMASPHERE (2020)
Iron overload in congenital haemolytic anaemias: role of hepcidin and cytokines and predictive value of ferritin and transferrin saturation
Wilma Barcellini et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study)
Elena M. Elli et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
The Role of New Technologies in Myeloproliferative Neoplasms
Giuseppe A. Palumbo et al.
FRONTIERS IN ONCOLOGY (2019)
Iron mobilization in a real life cohort of aplastic anemia patients treated with eltrombopag
Bruno Fattizzo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Iron Chelation Therapy in MDS - The Final Answer
Emanuele Angelucci et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes
Amer M. Zeidan et al.
ANNALS OF HEMATOLOGY (2019)
Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib
Elena Maria Elli et al.
FRONTIERS IN ONCOLOGY (2019)
Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience
Elena Maria Elli et al.
BLOOD (2019)
Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?
Ambra Di Veroli et al.
LEUKEMIA RESEARCH (2019)
Hepatic and cardiac and iron overload detected by T2*magnetic resonance (MRI) in patients with myelodisplastic syndrome: A cross-sectional study
L. F. Mantovani et al.
LEUKEMIA RESEARCH (2019)
Treatment of Anemia in Transfusion-Dependent and Non-Transfusion-Dependent Lower-Risk MDS: Current and Emerging Strategies
Ulrich Germing et al.
HEMASPHERE (2019)
Beta-thalassemia: renal complications and mechanisms: a narrative review
Christos Demosthenous et al.
HEMATOLOGY (2019)
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study
Francesca Palandri et al.
HEMATOLOGICAL ONCOLOGY (2018)
Serum ferritin is a different predictor from transfusion history for allogeneic transplantation outcome in patients with severe aplastic anemia
Xiaoyu Zhang et al.
HEMATOLOGY (2018)
Iron overload in myelodysplastic syndromes (MDS)
Norbert Gattermann
INTERNATIONAL JOURNAL OF HEMATOLOGY (2018)
Iron toxicity - Its effect on the bone marrow
Alessandro Isidori et al.
BLOOD REVIEWS (2018)
A storm in the niche: Iron, oxidative stress and haemopoiesis
Federica Pilo et al.
BLOOD REVIEWS (2018)
To chelate or not to chelate in MDS: That is the question!
Amer M. Zeidan et al.
BLOOD REVIEWS (2018)
Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes
Antonis Kattamis et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
Assessment of liver and cardiac iron overload using MRI in patients with chronic anemias in Latin American countries: results from ASIMILA study
Rodolfo Cancado et al.
HEMATOLOGY (2018)
Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients
Maura Nicolosi et al.
LEUKEMIA (2018)
Myelodysplastic Syndromes, Version 2.2017 Clinical Practice Guidelines in Oncology
Peter L. Greenberg et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia
D. A. C. Fisher et al.
LEUKEMIA (2017)
Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia
John B. Porter et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2017)
Impact of TET2 deficiency on iron metabolism in erythroblasts
Kyoko Inokura et al.
EXPERIMENTAL HEMATOLOGY (2017)
Erythroid response during iron chelation therapy in a cohort of patients affected by hematologic malignancies and aplastic anemia with transfusion requirement and iron overload: a FISM Italian multicenter retrospective study
Emanuela Messa et al.
LEUKEMIA & LYMPHOMA (2017)
Unraveling the mechanisms behind iron overload and ineffective hematopoiesis in myelodysplastic syndromes
Emanuele Angelucci et al.
LEUKEMIA RESEARCH (2017)
Synergistic inhibitory effects of deferasirox in combination with decitabine on leukemia cell lines SKM-1, THP-1, and K-562
Nianyi Li et al.
ONCOTARGET (2017)
Splicing factor SF3B1K700E mutant dysregulates erythroid differentiation via aberrant alternative splicing of transcription factor TAL1
Shuiling Jin et al.
PLOS ONE (2017)
Myelofibrosis-Related Anemia: Current and Emerging Therapeutic Strategies
Leonard Naymagon et al.
HEMASPHERE (2017)
Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator
Evangelia Vlachodimitropoulou et al.
BLOOD (2017)
Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis
Heather A. Leitch et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome
Amer M. Zeidan et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Acute kidney injury in allopurinol-induced DRESS syndrome: a case report of concurrent tubulointerstitial nephritis and kidney-limited necrotizing vasculitis
Anthony J. Esposito et al.
CLINICAL NEPHROLOGY (2017)
Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study
Pellegrino Musto et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study
Ali T. Taher et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Ineffective erythropoiesis and regulation of iron status in iron loading anaemias
Clara Camaschella et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Oxidative stress levels are correlated with P15 and P16 gene promoter methylation in myelodysplastic syndrome patients
Ana Cristina Goncalves et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2016)
Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders
Louise de Swart et al.
HAEMATOLOGICA (2016)
Clinical monitoring and management of complications related to chelation therapy in patients with beta-thalassemia
Antoine N. Saliba et al.
EXPERT REVIEW OF HEMATOLOGY (2016)
Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders
Louise de Swart et al.
HAEMATOLOGICA (2016)
Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes
Nicole Carreau et al.
BLOOD REVIEWS (2016)
Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9
Rebekka K. Schneider et al.
NATURE MEDICINE (2016)
The potential of deferasirox as a novel therapeutic modality in gastric cancer
Jung Hye Choi et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2016)
Deferasirox chelation therapy in patients with transfusion-dependent MDS: a real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata
Luca Maurillo et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2015)
Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications
Angel F. Remacha et al.
ANNALS OF HEMATOLOGY (2015)
Deferasirox effect on renal haemodynamic parameters in patients with transfusion-dependent β thalassaemia
Antonio Piga et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia
Ali T. Taher et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron
V. Visconte et al.
LEUKEMIA (2015)
Influence of single-nucleotide polymorphisms on deferasirox Ctrough levels and effectiveness
J. Cusato et al.
PHARMACOGENOMICS JOURNAL (2015)
Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome
Niraj Shenoy et al.
BLOOD (2014)
The impact of chelation therapy on survival in transfusional iron overload: a meta-analysis of myelodysplastic syndrome
Arch G. Mainous et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Clinical Pharmacology of Deferasirox
Chiaki Tanaka
CLINICAL PHARMACOKINETICS (2014)
Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial)
Emanuele Angelucci et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
Correlation of Iron Overload and Glomerular Filtration Rate Estimated by Cystatin C in Patients with β-Thalassemia Major
Murtadha Al-Khabori et al.
HEMOGLOBIN (2014)
Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry
Roger M. Lyons et al.
LEUKEMIA RESEARCH (2014)
Drug-induced renal Fanconi syndrome
A. M. Hall et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2014)
Atherogenesis and iron: from epidemiology to cellular level
Francesca Vinchi et al.
FRONTIERS IN PHARMACOLOGY (2014)
Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis
Animesh Pardanani et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload
F. Nolte et al.
ANNALS OF HEMATOLOGY (2013)
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
Francisco Cervantes et al.
BLOOD (2013)
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet
Luca Malcovati et al.
BLOOD (2013)
Hyperchloraemic metabolic acidosis induced by the iron chelator deferasirox: a case report and review of the literature
V. G. Dell'Orto et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2013)
Potential mechanisms for renal damage in beta-thalassemia
Naji S. Mallet et al.
JOURNAL OF NEPHROLOGY (2013)
Pharmacogenetic Study of Deferasirox, an Iron Chelating Agent
Ji Won Lee et al.
PLOS ONE (2013)
Transfusion-dependent low-risk myelodysplastic patients receiving deferasirox: Long-term follow-up
Salvatore Improta et al.
ONCOLOGY LETTERS (2013)
Deferasirox treatment for myelodysplastic syndromes: real-life efficacy and safety in a single-institution patient population
Massimo Breccia et al.
ANNALS OF HEMATOLOGY (2012)
Non-transferrin bound iron: A key role in iron overload and iron toxicity
Pierre Brissot et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2012)
Deferasirox treatment of iron-overloaded chelation-naive and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange
Norbert Gattermann et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2012)
Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion-Dependent Patients With Myelodysplastic Syndrome
Alan F. List et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience
Ayalew Tefferi et al.
MAYO CLINIC PROCEEDINGS (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Advances in the Management of Myelofibrosis
Rami S. Komrokji et al.
CANCER CONTROL (2012)
Controversies surrounding iron chelation therapy for MDS
Heather A. Leitch
BLOOD REVIEWS (2011)
Renal dysfunction in patients with thalassaemia
Charles T. Quinn et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias
John B. Porter et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
Absence of an effect of a single-dose deferasirox on the steady-state pharmacokinetics of digoxin
R. Sechaud et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Hepcidin Levels and Their Determinants in Different Types of Myelodysplastic Syndromes
Valeria Santini et al.
PLOS ONE (2011)
Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial
Jong Wook Lee et al.
BLOOD (2010)
Renal complications in transfusion-dependent beta thalassaemia
Claudio Ponticelli et al.
BLOOD REVIEWS (2010)
Incidence and Clinical Complications of Myelodysplastic Syndromes Among United States Medicare Beneficiaries
Stuart L. Goldberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM
Christian Rose et al.
LEUKEMIA RESEARCH (2010)
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study
Norbert Gattermann et al.
LEUKEMIA RESEARCH (2010)
Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines
V. Santini et al.
LEUKEMIA RESEARCH (2010)
Deferasirox (Exjade®) for the Treatment of Iron Overload
M. D. Cappellini et al.
ACTA HAEMATOLOGICA (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Consensus statement on iron overload in myelodysplastic syndromes
John M. Bennett
AMERICAN JOURNAL OF HEMATOLOGY (2008)
Effect of deferasirox (ICL670) on arterial function in patients with beta-thalassaemia major
Y. F. Cheung et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Iron chelation therapy in the myelodysplastic syndromes and aplastic anemia: a review of experience in South Korea
Jong Wook Lee
INTERNATIONAL JOURNAL OF HEMATOLOGY (2008)
Acute kidney injury following proton pump inhibitor therapy
U. C. Brewster et al.
KIDNEY INTERNATIONAL (2007)
Current concepts in the pathophysiology and treatment of aplastic anemia
Neal S. Young et al.
BLOOD (2006)
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia
MD Cappellini et al.
BLOOD (2006)
Renal tubular dysfunction in β-thalassemia minor
T Cetin et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2003)
Share Paper
